(VIANEWS) – The NASDAQ opens in less than two hours and Exact Sciences‘s pre-market value is already 4.32% up.
Exact Sciences’s last close was $67.82, 19.56% under its 52-week high of $84.31.
The last session, NASDAQ finished with Exact Sciences (EXAS) dropping 1.09% to $67.82. NASDAQ fell 1.68% to $11,910.52, following the last session’s downward trend on what was an all-around down trend trading session.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-5.61.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.71%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20%, now sitting on 1.94B for the twelve trailing months.
Moving Average
Exact Sciences’s value is way higher than its 50-day moving average of $54.41 and way above its 200-day moving average of $45.73.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 32.8% and 24%, respectively.
Volume
Today’s last reported volume for Exact Sciences is 1504053 which is 53.87% below its average volume of 2576440.
More news about Exact Sciences (EXAS).
